Market Place
Sourcing Support
ProQR Therapeutics Secures $8.1M from Rett Syndrome Research Trust
11 Dec 2024 //
GLOBENEWSWIRE
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
10 Dec 2024 //
GLOBENEWSWIRE
ProQR Hosts Virtual Analyst Event on December 11, 2024
05 Dec 2024 //
GLOBENEWSWIRE
ProQR Announces Q3 2024 Operating & Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
ProQR Closes Underwritten Public Offering and Private Placement
25 Oct 2024 //
GLOBENEWSWIRE
ProQR Proposes Underwritten Public Offering Of Shares
22 Oct 2024 //
GLOBENEWSWIRE
ProQR Prices $75M Public Offering And Private Placement
22 Oct 2024 //
GLOBENEWSWIRE
ProQR Highlights Upcoming Presentation At Oligonucleotide Meeting
07 Oct 2024 //
GLOBENEWSWIRE
ProQR Announces Webcast At Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
ProQR Announces Second Quarter 2024 Operating and Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
ProQR To Present On Axiomer™ RNA Editing At RNA Summit
18 Jun 2024 //
GLOBENEWSWIRE
ProQR Announces First Quarter 2024 Operating and Financial Results
09 May 2024 //
GLOBENEWSWIRE
ProQR NTCP RNA Editing Data For Cholestatic Diseases
08 May 2024 //
GLOBENEWSWIRE
ProQR Nominates Maier to Board, Announces May 22 Shareholder Meeting
23 Apr 2024 //
GLOBENEWSWIRE
ProQR Highlighting Axiomer RNA Editing At ASGCT 2024
22 Apr 2024 //
GLOBENEWSWIRE
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
19 Apr 2024 //
GLOBENEWSWIRE
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
ProQR Highlights New Platform Data from Presentation on Axiomer Technology
19 Jan 2024 //
GLOBENEWSWIRE
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer Collaboration
05 Jan 2024 //
GLOBENEWSWIRE
ProQR Announces Transaction Completed for Théa to Acquire Sepofarsen
08 Dec 2023 //
GLOBENEWSWIRE
ProQR Announces Third Quarter 2023 Operating and Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
ProQR Strengthens Intellectual Property Estate for ADAR-mediated RNA Editing
06 Nov 2023 //
GLOBENEWSWIRE
ProQR Announces Participation in Chardan 7th Annual Genetic Medicines Conference
28 Sep 2023 //
GLOBENEWSWIRE
ProQR Therapeutics Provides Update on Ophthalmic Assets
27 Sep 2023 //
GLOBENEWSWIRE
ProQR Announces Webcast at HC Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
ProQR Announces Second Quarter 2023 Operating and Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
ProQR & Laboratoires Théa Announce Agreement to Acquire ProQR’s Sepofarsen
01 Aug 2023 //
GLOBENEWSWIRE
ProQR has inked a deal with French company Laboratoires Théa
01 Aug 2023 //
ENDPTS
ProQR finds eye disease partner in Europe, hands off two late-stage candidates
01 Aug 2023 //
ENDPTS
ProQR offloads 2 eye disease assets to Théa for $14M upfront
01 Aug 2023 //
FIERCE BIOTECH
ProQR to Present Data on its Axiomer® RNA Editing Technology RNA Editing Summit
06 Jul 2023 //
GLOBENEWSWIRE
ProQR Announces First Quarter 2023 Operating and Financial Results
16 May 2023 //
GLOBENEWSWIRE
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
09 May 2023 //
GLOBENEWSWIRE
ProQR Announces Upcoming Investor Conferences in April and May
20 Apr 2023 //
GLOBENEWSWIRE
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
18 Apr 2023 //
GLOBENEWSWIRE
ProQR Announces Pipeline Targets and Highlights Axiomer RNA Editing Platform
29 Mar 2023 //
GLOBENEWSWIRE
ProQR Announces Defense of Axiomer Patent Protecting ADAR-mediated RNA Editing
14 Mar 2023 //
GLOBENEWSWIRE
ProQR to Present at Upcoming Scientific and Industry Conferences
07 Mar 2023 //
GLOBENEWSWIRE
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
28 Feb 2023 //
GLOBENEWSWIRE
Lilly pays $75M to widen RNA editing deal with ProQR
23 Dec 2022 //
BIOPHARMADIVE
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
21 Dec 2022 //
GLOBENEWSWIRE
ProQR to Present its Axiomer® RNA Editing Technology at Oligonucleotide &Peptide
14 Nov 2022 //
GLOBENEWSWIRE
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Conference
03 Nov 2022 //
GLOBENEWSWIRE
Korea establishes novel strategy to tackle Huntington’s disease?
13 Sep 2022 //
BIOSPECTRUMASIA
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner
11 Aug 2022 //
GLOBENEWSWIRE
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
28 Jun 2022 //
GLOBENEWSWIRE
ProQR Announces Annual General Meeting of Shareholders
01 Jun 2022 //
GLOBENEWSWIRE
ProQR to Present its Axiomer RNA Editing Technology at the TIDES USA 2022
09 May 2022 //
GLOBENEWSWIRE
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit
26 Apr 2022 //
GLOBENEWSWIRE
ProQR to Participate in the Kempen Life Sciences Conference
19 Apr 2022 //
GLOBENEWSWIRE
ProQR to lay off 30% of staff following eye drug setback
14 Apr 2022 //
BIOPHARMADIVE
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses
13 Apr 2022 //
GLOBENEWSWIRE
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
04 Apr 2022 //
GLOBENEWSWIRE
ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit
23 Mar 2022 //
GLOBENEWSWIRE
ProQR Appoints John Maraganore, PhD, as Strategic Advisor
07 Mar 2022 //
GLOBENEWSWIRE
ProQR Announces Q4 and Full Year 2021 Operating and Financial Results
24 Feb 2022 //
GLOBENEWSWIRE
ProQR eye drug comes up short in key study, surprising company and investors
12 Feb 2022 //
BIOPHARMADIVE
ProQR Shows Results from Phase 2/3 Illuminate Trial of Sepofarsen
11 Feb 2022 //
GLOBENEWSWIRE
ProQR to Present at Upcoming SVB Leerink Conference
07 Feb 2022 //
GLOBENEWSWIRE
